首頁 > 市場調查報告書 > 製藥

疫苗動物用醫藥

市場調查報告書

商品編碼

1735663

全球豬疫苗市場規模（按適應症、技術、地區和預測）

Global Porcine Vaccine Market Size By Disease Indication (Swine Influenza, Diarrhea, Arthritis), By Technology (Inactivated vaccines, Live attenuated vaccines, Recombinant vaccines), By Geographic Scope And Forecast

出版日期: 2025年05月02日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

豬疫苗市場規模及預測

2024 年豬疫苗市場規模價值 21.9 億美元，預計到 2032 年將達到 38.3 億美元，2026 年至 2032 年的複合年成長率為 7.27%。

推動全球豬隻疫苗市場成長的主要因素是豬肉消費量的增加和豬病的流行。此外，世界各國政府都在增加對動物保健領域的支出。全球豬疫苗市場報告對預測期內的市場進行了總體評估。報告分析了各個細分市場以及在市場中發揮重要作用的趨勢和因素。

定義全球豬疫苗市場

疫苗是預防動物和人類疾病最重要的工具。疫苗接種在動物用藥品中被認為是一項福音，可以預防許多地方性疾病的傳播並保障動物福利。豬疫苗在臨床上用於改善豬的健康狀況，並透過保護豬免受病毒、細菌和其他病原體的侵害來預防致命疾病。

這些疾病包括豬繁殖與呼吸道病毒（PRRSV）、豬流感和豬環狀病毒相關疾病（PCVAD）。它還能提高保護豬免受致命病毒侵害的整體效率，並增加供人類食用的優質肉類的產量。在北美和歐洲，霍亂和口蹄疫等多種疾病已透過使用這些疫苗而基本被消滅。

全球豬隻疫苗市場概況

豬肉消費量的增加是全球豬隻疫苗市場的主要驅動力。預計消費量的增加將增加保護豬群免受任何可能影響豬隻並對人類構成威脅的疾病的需求。這預計將推動對用於預防各種豬病的豬疫苗的需求。

由於全球豬流感、豬隻流行性腹瀉（PED）和豬隻繁殖與呼吸症候群（PRRS）病例不斷增加，仔豬早期免疫接種率也有所提高。其他重要推動因素包括加強對豬病的宣傳，以及政府增加對獸醫的資助。

技術進步和研發投入的不斷擴大預計將帶來新的商機，從而推動全球豬隻疫苗市場的成長。聯合疫苗的生產提供了良好的成長機會。此外，DNA疫苗還能幫助農民在農場生產無病豬。因此，市場擁有充足的成長機會。然而，疫苗的維護、運輸和儲存成本高昂等一些阻礙因素預計將對豬疫苗產業的成長產生不利影響。

Some of the key contributing factors propelling the growth of the Global Porcine Vaccine Market are an increase in pork consumption and a rise in the prevalence of swine diseases. Also, governments across the globe are spending higher in the field of animal health care. The Global Porcine Vaccine Market report provides a holistic evaluation of the market for the forecast period. The report comprises various segments as well as an analysis of the trends and factors that are playing a substantial role in the market.

Global Porcine Vaccine Market Definition

Vaccines are the most important disease prevention tools for both animals and humans. Vaccination is regarded as a boon in veterinary pharmaceuticals for preserving animal welfare by avoiding the spread of many endemic diseases. Porcine vaccines are used clinically to improve swine health and protect them from deadly diseases by guarding them against viruses, bacteria, and other pathogens.

Such diseases include porcine reproductive and respiratory virus (PRRSV), swine influenza, and porcine circovirus-associated disease (PCVAD) among others. It also increases the yield of high-quality meat for human consumption while improving overall efficiency in protecting pigs from deadly viruses. In North America and Europe, many diseases like cholera, foot & mouth disease have been significantly eliminated by using these vaccines.

Global Porcine Vaccine Market Overview

The increase in pork consumption is an important driver for the Global Porcine Vaccine Market. This increase in consumption is expected to result in a greater need to keep the swine population free of any disease that could affect them and pose a threat to humans. Thus the demand for swine vaccines that guards against various porcine diseases is expected to rise.

Also, higher instances of swine flu, porcine epidemic diarrhea (PED), and porcine reproductive and respiratory syndrome (PRRS) in farms worldwide have led to an increase in early vaccination of piglets. Other important drivers are the increasing number of awareness programs about porcine diseases and increased government funding for animal health care.

Technological advancements and growing research and development are expected to provide new profitable opportunities leading to the growth of the Global Porcine Vaccine Market. Combined vaccine production gives a good opportunity for growth. Also, DNA vaccines allow agriculture farmers to produce disease-free swine on their farms. Thus, there are ample growth opportunities for the market. However, there are some restraints like the high cost of maintaining, transportation, and storage of vaccines that are expected to adversely impact the growth of the Porcine Vaccine industry.

Global Porcine Vaccine Market Segmentation Analysis

The Global Porcine Vaccine Market is segmented on the basis of Disease Indication, Technology, And Geography.

Porcine Vaccine Market, By Disease Indication

Swine Influenza
Diarrhea
Arthritis
Porcine Reproductive and Respiratory Syndrome
Porcine Circovirus Associated Disease
Others

Based on Disease Indication, The market is segmented into Swine Influenza, Diarrhea, Arthritis, Porcine Reproductive and Respiratory Syndrome, Porcine Circovirus Associated Disease, and Others. Diarrhea and swine influenza dominate the Global Porcine Vaccine Market owing to factors like changes in climate including global warming and overfeeding of protein diet among others.

Porcine Vaccine Market, By Technology

Inactivated vaccines
Live attenuated vaccines
Recombinant vaccines
DNA vaccines
Others

Based on Technology, The market is segmented into Inactivated vaccines, Live attenuated vaccines, Recombinant vaccines, DNA vaccines, and Others. Inactivated vaccines are leading the market. DNA vaccines are gaining popularity in veterinary hospitals as they have several advantages over live attenuated vaccines and inactivated vaccines.

Porcine Vaccine Market, By Geography

North America
Europe
Asia Pacific
Rest of the world
On the basis of Geography, The Global Porcine Vaccine Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America leads the Global Porcine Vaccine Market by geography due to the rise in pork consumption, increasing instances of various swine diseases, and higher per-capita animal healthcare expenditure in the United States. The Asia Pacific region will have good growth due to increasing awareness about porcine health, and growing advancements in the field of biotechnology.

Key Players

The "Global Porcine Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Bayer AG, Hipra, Ceva Sante Animale, Eli Lilly and Company, Merck & Co. Inc., Sanofi S.A, Zoetis Inc., Arko Laboratories Ltd, and Vetoquinol. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

On August 5, 2021 Bayer AG announced the acquisition of Vividion Therapeutics, Inc. (Vividion), a US-based biopharmaceutical company that specializes in novel detection technology to unlock high-volume, uncontrolled traditional therapies with specific therapies. The Vividion platform is capable of producing a wide range of therapeutic approaches to small molecules in all directions, with an initial focus on oncology and immunology. Vividion's leading programs include a wide range of oncology specification and immunology guidelines, with ongoing efforts to counteract NRF2 antagonism for the possible treatment of NRF2 cancer, and NRF2 activists for various inflammatory diseases such as acute intestinal disease - among other treatment programs.
On February 18, 2021 Philippe Mauguin, INRAE chief executive officer and Drs. Marc Prikazsky, Chairman and CEO of Ceva Sante Animale (Ceva), signed a first-round agreement aimed at consolidating their animal health partnerships. This signature comes in the context of Covid-19 disease and the outbreak of bird flu in France. It affirms the shared goal of working together for the "One Health", global health concept at animal crossroads, human and environmental health and, in particular, to prevent infectious diseases from the environment and to improve animal welfare.

1 INTRODUCTION OF GLOBAL PORCINE VACCINE MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL PORCINE VACCINE MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model

5 GLOBAL PORCINE VACCINE MARKET, BY DISEASE INDICATION

5.1 Introduction
5.2 Swine Influenza
5.3 Diarrhea
5.4 Arthritis
5.5 Porcine Reproductive and Respiratory Syndrome
5.6 Porcine Circovirus Associated Disease
5.7 Others

6 GLOBAL PORCINE VACCINE MARKET, BY TECHNOLOGY

6.1 Introduction
6.2 Inactivated vaccines
6.3 Live attenuated vaccines
6.4 Recombinant vaccines
6.5 DNA vaccines
6.6 Others

7 GLOBAL PORCINE VACCINE MARKET, BY GEOGRAPHY

7.1 Overview
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.2.3 Mexico
7.3 Europe
- 7.3.1 Germany
- 7.3.2 U.K.
- 7.3.3 France
- 7.3.4 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Rest of Asia Pacific
7.5 Rest of the World
- 7.5.1 Middle East and Africa
- 7.5.2 South America

8 GLOBAL PORCINE VACCINE MARKET COMPETITIVE LANDSCAPE

8.1 Overview
8.2 Company Market Ranking
8.3 Key Development Strategies

9 COMPANY PROFILES

9.1 Merial
- 9.1.1 Overview
- 9.1.2 Financial Performance
- 9.1.3 Product Outlook
- 9.1.4 Key Developments
9.2 Zoetis Inc.
- 9.2.1 Overview
- 9.2.2 Financial Performance
- 9.2.3 Product Outlook
- 9.2.4 Key Developments
9.3 Intervet Inc.
- 9.3.1 Overview
- 9.3.2 Financial Performance
- 9.3.3 Product Outlook
- 9.3.4 Key Developments
9.4 Vetoquinol
- 9.4.1 Overview
- 9.4.2 Financial Performance
- 9.4.3 Product Outlook
- 9.4.4 Key Developments
9.5 Bayer AG
- 9.5.1 Overview
- 9.5.2 Financial Performance
- 9.5.3 Product Outlook
- 9.5.4 Key Developments
9.6 IDT Biologika GmbH
- 9.6.1 Overview
- 9.6.2 Financial Performance
- 9.6.3 Product Outlook
- 9.6.4 Key Developments
9.7 HIPRA
- 9.7.1 Overview
- 9.7.2 Financial Performance
- 9.7.3 Product Outlook
- 9.7.4 Key Developments
9.8 Ceva Sante Animale
- 9.8.1 Overview
- 9.8.2 Financial Performance
- 9.8.3 Product Outlook
- 9.8.4 Key Developments
9.9 Elanco
- 9.9.1 Overview
- 9.9.2 Financial Performance
- 9.9.3 Product Outlook
- 9.9.4 Key Developments
9.10 Arko Laboratories Ltd
- 9.10.1 Overview
- 9.10.2 Financial Performance
- 9.10.3 Product Outlook
- 9.10.4 Key Developments